Novartis Pharmaceuticals
Mitoxantrone Hydrochloride(Novartis Pharmaceuticals)은 Acute Myeloid Leukemia 표적 ADC로, Leukemia; Myelodysplastic Syndromes 영역에서 개발·상용화 중입니다. Phase 2에서 효능·안전성 신호를 검증 중입니다. OS: 564. PK: t½ 215 days. 차별점: novel tracer for lymphatic mapping and complication reduction in thyroid cancer surgery: A single-center, randomized clinical.
Acute Myeloid Leukemia
Leukemia; Myelodysplastic Syndromes
Active
novel tracer for lymphatic mapping and complication reduction in thyroid cancer surgery: A single-center, randomized clinical
DNA damage signaling, thereby reducing the thermal resistance effect and establishing synergistic chemo-photothermal therapy
downregulation
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Novartis Pharmaceuticals
Mitoxantrone Hydrochloride(Novartis Pharmaceuticals)은 Acute Myeloid Leukemia 표적 ADC로, Leukemia; Myelodysplastic Syndromes 영역에서 개발·상용화 중입니다. Phase 2에서 효능·안전성 신호를 검증 중입니다. OS: 564. PK: t½ 215 days. 차별점: novel tracer for lymphatic mapping and complication reduction in thyroid cancer surgery: A single-center, randomized clinical.
Acute Myeloid Leukemia
Leukemia; Myelodysplastic Syndromes
Active
novel tracer for lymphatic mapping and complication reduction in thyroid cancer surgery: A single-center, randomized clinical
DNA damage signaling, thereby reducing the thermal resistance effect and establishing synergistic chemo-photothermal therapy
downregulation
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.